2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome
2ME2 inhibits triple negative breast cancer by impacting major cellular processes like proliferation, apoptosis, metastasis, etc. It further modifies gene expression by altering the miRNome of triple negative breast cancer cells. Overall, our findings suggest 2ME2 as a potent anti-cancer drug for the treatment of TNBC.
Authors
- Seeta Poudel (ORCID: https://orcid.org/0000-0001-6834-5644)
- Diego A. Pedroza (ORCID: https://orcid.org/0000-0002-7355-2952)
- Elizabeth Penner (ORCID: https://orcid.org/0009-0009-4325-1911)
- Preetha Rajkumar
- Ramadevi Subramani (ORCID: https://orcid.org/0000-0002-1054-0903)
- Rajkumar Lakshmanaswamy
- Jeffrey Annabi
- A. Chatterjee (ORCID: https://orcid.org/0000-0002-2935-0958)
Institutions
- Rocky Vista University (US)
- Texas Tech University (US)
- The University of Texas at El Paso (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-12
- DOI
- https://doi.org/10.3389/fonc.2024.1371792
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Texas Tech University